![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
Aim: This study aims to establish the potential reliability and validity of miRNA-182 as a diagnostic tool in oncology, and hence to contribute to the decision-making process in clinical settings. Materials & methods: To further evaluate the role of miRNA-182 as a cancer biomarker, we conducted a search of the PubMed, Cochrane Library, Wanfang and China National Knowledge Infrastructure databases of existing literature. Conclusion: These results suggest that miRNA-182 could function as a potential molecular marker for cancer detection and diagnosis. The effect of miRNA-182 on tumor development should be further studied to confirm these results and add to the current understanding of its role in cancer.
Plain language summary
A meta-analysis involves integrating the results from various studies to create a comprehensive understanding or view of the research topic. This review with meta-analysis presents an exhaustive evaluation of the effectiveness of a tiny molecule in our cells that helps control what our genes do named miRNA-182 as a signal that indicates a certain disease or condition for a variety of cancer types which we also called biomarkers. By assembling and analyzing a broad spectrum of research papers, the study assesses the specificity, sensitivity and overall diagnostic accuracy of miRNA-182 in cancer detection. The analysis incorporates diverse studies, ensuring an inclusive assessment of miRNA-182 across different types and stages of cancer.
The review presents data from numerous clinical trials and studies, providing an in-depth examination of the variations in miRNA-182 levels between cancer patients and healthy individuals. Meta-analysis findings suggest that miRNA-182 demonstrates high diagnostic precision, surpassing traditional biomarkers in certain instances. This evidence underscores its potential value in clinical settings, notably in cancers where early detection is essential for effective treatment.
Highlighting the emerging significance of miRNA biomarkers in the study of cancer, this review emphasizes the potential of miRNA-182 in enhancing early cancer detection, which could profoundly influence treatment outcomes. The findings propose that miRNA-182 may substantially improve early cancer detection and patient outcomes, indicating a substantial stride forward in tools and tests used to detect and understand cancer.
Finally, the review advocates for larger, more diverse sample sizes and standardization of methodologies. These improvements will further validate miRNA-182’s reliability as a cancer biomarker, establishing its diagnostic capabilities and promoting its integration into clinical practice.
Author contributions
M Shang and G Su: data collection and analysis, and original draft preparation. W Huang: further modifications and financial support to the article. All authors contributed to the article and agreed to the submitted version.
Acknowledgments
The authors would like to thank the contributions of universities, institutions and financial support.
Financial disclosure
This work was supported by the National Key R&D Program of China (2019YFA0906000), the National Natural Science Foundation of China (81972867,81773257), the Natural Science Foundation of Guangdong (2018B030306023), the Shenzhen Municipal Government of China (RCYX20200714114701035, JCYJ20180507184642475), the Shenzhen Key Medical Discipline Construction Fund (no. SZXK020), and the Natural Science Foundation of Shenzhen Science and Technology Innovation Committee (JCYJ20190806164616292). The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Competing interests disclosure
The authors have no competing interests or relevant affiliations with any organization or entity with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Writing disclosure
Medical writing support was provided by Editage and was funded by Guangdong Provincial Basic and Applied Basic Research Fund Natural Science Foundation Project (General Project).